Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Switzerland

European Research Council grant · Running

LIFE Targeting bioactive lipids to overcome leukemia immune evasion and improve allogeneic hematopoietic stem cell transplantation outcomes

Coordinator
Universitat Basel, Switzerland
Runs
1 January 2027 to 31 December 2031
Status
Running
EU funding
€1.5m
Total cost
€1.5m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101301617

What the project is doing

In the project's own words, from its summary on CORDIS.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can cure acute myeloid leukemia (AML) via the immunological graft-versus-leukemia (GVL) effect, but relapse through immune evasion is frequent and accounts for 50% of the allo-HSCT-related mortality. The current strategy for relapse relies on chemo- or targeted therapy combined with donor lymphocyte infusions. Still, only few patients achieve long-term cure, underlining the urgent need for a better mechanistic understanding and more effective treatments.

Our recent work indicates that metabolic adaptations in AML—induced by prior chemotherapy exposure—act as protective ""shields"" against anti-leukemia immunity. Notably, we identified the bioactive lipids phosphatidic acid (PA) and oxylipins as two such shields. With LIFE, we will test the concept that selected bioactive lipids drive AML relapse—and that blocking them can enhance the GVL response and improve allo-HSCT outcomes.

We will integrate lipidomics for bioactive lipid detection, spatial and single-cell technologies, and functional genomics with in vivo allo-HSCT models and primary human AML samples to define the molecular effects of PA (Aim 1) and oxylipins (Aim 2) on immune evasion. Importantly, we will test how targeting these axes synergizes with donor immune cells and improves leukemia control. In parallel, we will use focused in vitro and in vivo CRISPRi screens to discover lipid pathway genes whose inhibition sensitizes AML to combined chemo-immune pressure (Aim 3).

This project will, for the first time, delineate how AML-derived bioactive lipids orchestrate immune evasion and provide a rationale for combinations targeting these pathways to improve allo-HSCT outcomes. Beyond allo-HSCT, we will uncover fundamental principles of how bioactive lipids shape tumor–immune interactions. By turning the metabolic shields into vulnerabilities, LIFE will deliver novel entry points for next-generation cancer therapies.""

Topics

Who is involved

OrganisationCityCountryRole
Universitat BaselBaselSwitzerlandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS